(BPT) – Imagine waking up every day feeling utterly exhausted, no matter how much sleep you get. Now, add an unbearable itch that just won’t go away, dry eyes and mouth, and stomach pain. This is the ...
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of two per 100,000 people per year and an estimated prevalence of 15 per ...
Please provide your email address to receive an email when new articles are posted on . International Primary Biliary Cholangitis Day, celebrated on September 10, aspires to raise awareness of the ...
CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant ...
—A large international cohort study of patients with primary biliary cholangitis recently demonstrated that the most recent liver stiffness measurement is the single strongest, independent predictor ...
NEWARK, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic ...
Seladelpar, an investigational selective agonist of peroxisome proliferator–activated receptor-delta (PPAR-δ), significantly improves liver biomarkers of disease activity and bothersome symptoms of ...
– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi ® (seladelpar) ...
Gilead Sciences, Inc. today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi ® for people living with primary biliary cholangitis. These findings were presented at ...
Intercept Announces New PBC Data Analyses to be Presented at Digestive Disease Week® 2024 Conference
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and ...
The accelerated approval was based primarily on data from the pivotal placebo-controlled Phase 3 RESPONSE study. In the study, 62% of participants taking Livdelzi achieved the primary endpoint of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback